Reported Earlier, Iovance To Present Updated Clinical Data For Lifileucel In Combination With Pembrolizumab In Frontline Advanced Melanoma At ASCO Annual Meeting
Reported Earlier, Iovance To Present Updated Clinical Data For Lifileucel In Combination With Pembrolizumab In Frontline Advanced Melanoma At ASCO Annual Meeting
此前報道，Iovance將在ASCO年會上公佈Lifileucel與Pembrolizumab聯合用於前線晚期黑色素瘤的最新臨床數據
Response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy. These results strongly support the ongoing Phase 3 TILVANCE-301 clinical trial.
在對免疫檢查點抑制劑（ICI）治療不熟悉的一線晚期黑色素瘤患者中，觀察到反應率以及深度而持久的反應。這些結果有力地支持正在進行的 TILVANCE-301 三期臨床試驗。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。